
Opinion|Videos|May 30, 2024
Aligning With 2023 ESC Guidelines in oHCM Treatment
Author(s)Anjali Tiku Owens, MD
Anjali Tiku Owens, MD, explores the role of cardiac myosin inhibitors in the treatment strategies for patients with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with the latest European Society of Cardiology (ESC) Guidelines released in 2023.
Advertisement
Episodes in this series

- Where do cardiac myosin inhibitors fit into the treatment plans of your patients with oHMC, according to the most recent guidelines?
ESC Guidelines 2023
- Initiating cardiac myosin inhibitors earlier?
- Use in patients who are severely symptomatic?
- MAPLE-HCM trial
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Libre Duo 10 Day Authorized as First Glucose-Ketone Monitor for Diabetes
2
Psoriasis Awareness & Action Month: New Oral Drugs and Other Developments
3
FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer
4
TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD
5








































































